BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15262143)

  • 1. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.
    Chen LM; Lengyel ER; Bethan Powell C
    Gynecol Oncol; 2004 Jul; 94(1):204-7. PubMed ID: 15262143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study.
    Covens A; Filiaci VL; Burger RA; Osborne R; Chen MD;
    Cancer; 2006 Sep; 107(6):1280-6. PubMed ID: 16900525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy.
    Matsui H; Suzuka K; Yamazawa K; Tanaka N; Mitsuhashi A; Seki K; Sekiya S
    Gynecol Oncol; 2005 Mar; 96(3):616-20. PubMed ID: 15721402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
    Abrão RA; de Andrade JM; Tiezzi DG; Marana HR; Candido dos Reis FJ; Clagnan WS
    Gynecol Oncol; 2008 Jan; 108(1):149-53. PubMed ID: 17931696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
    J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
    Homesley HD
    J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
    Lurain JR; Nejad B
    Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia].
    Jiang J; Nan FF; Yang XS; Zhang YZ; Wang B; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):595-9. PubMed ID: 17983513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
    Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
    J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 30 years' experience in the treatment of low-risk gestational trophoblastic neoplasia in Hungary.
    Fülöp V; Szigetvári I; Szepesi J; Végh G; Bátorfi J; Nagymányoki Z; Török M; Berkowitz RS
    J Reprod Med; 2010; 55(5-6):253-7. PubMed ID: 20626182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia.
    Gilani MM; Yarandi F; Eftekhar Z; Hanjani P
    Aust N Z J Obstet Gynaecol; 2005 Apr; 45(2):161-4. PubMed ID: 15760322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients.
    Soper JT; Spillman M; Sampson JH; Kirkpatrick JP; Wolf JK; Clarke-Pearson DL
    Gynecol Oncol; 2007 Mar; 104(3):691-4. PubMed ID: 17137617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the response to chemotherapy in gestational trophoblastic neoplasia with vaginal metastases.
    Ghaemmaghami F; Behroozi S; Mousavi A; Ashrafgangooei T; Gilani MM; Behtash N; Ghanbari Z
    Arch Gynecol Obstet; 2008 Oct; 278(4):315-8. PubMed ID: 18293004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Rosa MW; Ayub AC; Graudenz Mda S; Schmid H
    Gynecol Oncol; 2009 Aug; 114(2):299-305. PubMed ID: 19427681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.